Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy

Introduction: Biomarkers predicting tumor response to neoadjuvant immunochemotherapy in non-small cell lung cancer (NSCLC) are still lacking despite great efforts. We aimed to assess the effectiveness of the immune PET Response Criteria in Solid Tumors via SULmax (iPERCIST-max) in predicting tumor r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Taotao, Huang, Shujie, Jiang, Yongluo, Yuan, Hui, Wu, Junhan, Liu, Chao, Zhang, Xiaochun, Tang, Yong, Ben, Xiaosong, Tang, Jiming, Zhou, Haiyu, Zhang, Dongkun, Xie, Liang, Chen, Gang, Zhao, Yumo, Wang, Shuxia, Xu, Hao, Qiao, Guibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582780/
https://www.ncbi.nlm.nih.gov/pubmed/36277407
http://dx.doi.org/10.3389/fbioe.2022.1010672

Ejemplares similares

Ejemplares similares